文献速递抗栓抗凝管理药物不良反应与药物警戒

跌倒致老年创伤性脑损伤中伤前口服抗凝药对结局的影响

Effect of Preinjury Oral Anticoagulants on Outcomes Following Traumatic Brain Injury from Falls in Older Adults.
PubMed 文献 · Pharmacotherapy · 2020-07-06

本研究基于29家创伤中心2012年至2018年6月的数据,纳入8312例65岁及以上因平地跌倒导致颅脑损伤(AIS头部分≥3)的患者,分析伤前使用抗凝或抗血小板药物与死亡或临终关怀联合结局的关系。多因素分析显示,伤前使用华法林(OR 1.60;95%CI 1.27-2.01)或DOAC(OR 1.67;95%CI 1.07-2.59)均增加死亡或临终关怀风险,而抗血小板治疗未增加风险。

要点

  • 伤前使用华法林或DOAC的老年TBI患者死亡或临终关怀风险增加。
  • 伤前抗血小板治疗未显示增加死亡或临终关怀风险。
  • 华法林联合抗血小板增加风险,而DOAC联合抗血小板未显示增加风险。

核心结论

  • 在老年创伤性脑损伤患者中,伤前使用华法林或DOAC与死亡或临终关怀风险增加相关。
  • 伤前抗血小板治疗未增加死亡或临终关怀风险。

研究设计与样本

  • 多中心回顾性队列研究,数据来自2012年至2018年6月29家一级和二级创伤中心。
  • 纳入8312例65岁及以上、平地跌倒、简明损伤定级(AIS)头部评分≥3的患者。
  • 排除无生命体征或非平地跌倒致伤者,采用多因素分析以抗凝/抗血小板药物使用为自变量。

主要发现

  • 华法林组185例(27.7%)和DOAC组43例(22.9%)发生死亡或临终关怀联合结局,无抗凝组为575例(15.8%)(p<0.001)。
  • 调整患者因素后,华法林组死亡或临终关怀风险OR 1.60(95%CI 1.27-2.01),DOAC组OR 1.67(95%CI 1.07-2.59),均高于无抗凝组。
  • 华法林联合抗血小板组死亡或临终关怀风险OR 1.61(95%CI 1.18-2.21),而DOAC联合抗血小板组OR 0.93(95%CI 0.46-1.87),后者未显示风险增加。

临床怎么用

  • 对跌倒致颅脑损伤的老年患者,应详细询问伤前抗凝药物使用史以评估风险。
  • 伤前使用华法林或DOAC者需警惕死亡或临终关怀风险升高,加强监测与救治。

局限性

  • 需要更大样本研究直接比较伤前华法林与DOAC使用相关的TBI结局。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Warfarin has been the oral anticoagulant of choice for the treatment of thromboembolic disease. However, upward of 50% of all new anticoagulant prescriptions are now for direct oral anticoagulants (DOAC). Despite this, outcome data evaluating preinjury anticoagulants remain scarce following traumatic brain injury (TBI). Our study objective is to determine the effects of preinjury anticoagulation on outcomes in older adults with TBI. METHODS: Patient data were obtained from 29 level 1 and 2 trauma centers from 2012 to June 30, 2018. Overall, 8312 patients who were aged 65 years or older, suffering a ground level fall, and with an Abbreviated Injury Scale (AIS) head score of ≥ 3 were identified. Patients were excluded if they presented with no signs of life or a traumatic mechanism besides ground level fall. Statistical comparisons were made using multivariable analyses with anticoagulant/antiplatelet use as the independent variable. RESULTS: Of the total patients with TBI, 3293 were on antiplatelet agents (AP), 669 on warfarin, 414 on warfarin + AP, 188 on DOACs, 116 on DOAC + AP, and 3632 on no anticoagulant. There were 185 (27.7%) patients on warfarin and 43 (22.9%) on a DOAC with a combined outcome of mortality or hospice as compared to 575 (15.8%) in the no anticoagulant group (p<0.001). After adjusting for patient factors, there was an increased risk of mortality or hospice in the warfarin (OR 1.60; 95% CI 1.27-2.01) and DOAC group (OR 1.67; 95% CI 1.07-2.59) as compared to no anticoagulant. Warfarin + AP was associated with an increased risk of mortality or hospice (OR 1.61; 95% CI 1.18-2.21) that was not seen with DOAC + AP (OR 0.93; 95% CI 0.46-1.87) as compared to no anticoagulant. CONCLUSIONS: In older adults with TBI, preinjury treatment with warfarin or DOACs resulted in an increased risk of mortality or hospice whereas preinjury AP therapy did not increase risk. Future studies are needed with larger sample sizes to directly compare TBI outcomes associated with preinjury warfarin versus DOAC use.

来源:Pharmacotherapy,查看原文。版权归原作者所有。

引用

  1. Hecht JP, LaDuke ZJ, Cain-Nielsen AH, et al. Effect of Preinjury Oral Anticoagulants on Outcomes Following Traumatic Brain Injury from Falls in Older Adults. Pharmacotherapy. 2020. PMID: 32515829. doi:10.1002/phar.2435

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。